financial news
Aside from Xtandi, Pfizer Inc. said Medivation also has a promising
pipeline of cancer drugs in late-stage clinical development. That
includes the potential breast cancer treatment talazoparib and a
potential lymphoma drug.
Talazoparib,
an orally available poly-ADP ribose polymerase, or PARP, inhibitor, is
currently in a Phase 3 clinical trial for the treatment of patients with
gBRCA mutated breast cancer (i.e., advanced breast cancer in patients
whose BRCA genes contain germline mutations). In addition, we are
targeting a number of other solid tumor indications in which to
investigate talazoparib, including breast (beyond gBRCA mutations),
prostate, small cell lung, and ovarian cancers.
~~~~~~~~~~
Note: gBRCA = BRCA1/2
0 comments :
Post a Comment
Your comments?